Evidence map›Paper›PMID 34069795›Full record

ArticleCancers2021

Iodine Map Radiomics in Breast Cancer: Prediction of Metastatic Status.

Lukas Lenga, Simon Bernatz, Simon S Martin, Christian Booz, Christine Solbach, Rotraud Mulert-Ernst, Thomas J Vogl, Doris Leithner

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lukas LengaDepartment of Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Simon BernatzDepartment of Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Simon S MartinDepartment of Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Christian BoozDepartment of Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Christine SolbachDepartment of Gynecology and Obstetrics, University Hospital Frankfurt, 60590 Frankfurt, Germany.ORCID 0000-0001-8284-3199
Rotraud Mulert-ErnstDepartment of Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Thomas J VoglDepartment of Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Doris LeithnerDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Dual-energy CT (DECT) iodine maps enable quantification of iodine concentrations as a marker for tissue vascularization. We investigated whether iodine map radiomic features derived from staging DECT enable prediction of breast cancer metastatic status, and whether textural differences exist between primary breast cancers and metastases. Seventy-seven treatment-naïve patients with biopsy-proven breast cancers were included retrospectively (41 non-metastatic, 36 metastatic). Radiomic features including first-, second-, and higher-order metrics as well as shape descriptors were extracted from volumes of interest on iodine maps. Following principal component analysis, a multilayer perceptron artificial neural network (MLP-NN) was used for classification (70% of cases for training, 30% validation). Histopathology served as reference standard. MLP-NN predicted metastatic status with AUCs of up to 0.94, and accuracies of up to 92.6 in the training and 82.6 in the validation datasets. The separation of primary tumor and metastatic tissue yielded AUCs of up to 0.87, with accuracies of up to 82.8 in the training, and 85.7 in the validation dataset. DECT iodine map-based radiomic signatures may therefore predict metastatic status in breast cancer patients. In addition, microstructural differences between primary and metastatic breast cancer tissue may be reflected by differences in DECT radiomic features.

Indexed as

breast cancercomputed tomographydual-energyradiomics

Identifiers

PMID34069795
PMCPMC8157278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.